Several analysts have recently updated their ratings and price targets for Karyopharm Therapeutics (NASDAQ: KPTI):

  • 11/30/2016 – Karyopharm Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/25/2016 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/22/2016 – Karyopharm Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/17/2016 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/11/2016 – Karyopharm Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/8/2016 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $12.00 price target on the stock.
  • 11/8/2016 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
  • 11/8/2016 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
  • 11/8/2016 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity.
  • 10/7/2016 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $18.00 price target on the stock.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) opened at 9.23 on Thursday. The stock’s market capitalization is $380.67 million. Karyopharm Therapeutics Inc. has a 52 week low of $4.83 and a 52 week high of $19.38. The stock has a 50 day moving average price of $8.72 and a 200 day moving average price of $8.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.69) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. On average, equities research analysts expect that Karyopharm Therapeutics Inc. will post ($3.00) EPS for the current year.

In related news, insider Ran Frenkel sold 3,309 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $10.06, for a total value of $33,288.54. Following the sale, the insider now directly owns 14,691 shares of the company’s stock, valued at $147,791.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.79% of the stock is owned by corporate insiders.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.